Literature DB >> 16960119

Immunoglobulin G, A, and M responses to BK virus in renal transplantation.

Parmjeet S Randhawa1, Gaurav Gupta, Abhay Vats, Ron Shapiro, Raphael P Viscidi.   

Abstract

Immunoglobulin G (IgG), IgA, and IgM antibodies were measured in serum samples from 71 organ donors, 81 kidney transplant recipients at transplantation, and 67 patients during the posttransplant period by using a virus-like particle-based enzyme-linked immunosorbent assay (ELISA). BK virus (BKV) and JC virus DNA were detected in urine and plasma by real-time PCR. IgG antibodies to BKV were demonstrated in the majority (80.3 to 100%) of patients irrespective of clinical category, but titers were highest in patients with active viral replication. IgA antibodies were present with greater frequency (72.7 to 81.3% versus 0 to 23.6%; P < 0.001) and higher titer (mean optical density, 0.11 to 0.15 versus 0.05 to 0.08; P < 0.001) in patients who were BKV DNA positive than those who were BKV DNA negative. IgM antibodies showed a similar pattern of reactivity but lower frequency in the setting of active viral replication (9.1 to 43.7% versus 0 to 1.4%; P < 0.001). A rise in IgG level of >0.577 optical density (OD) units or a rise in IgA or IgM level of >0.041 OD units was strongly associated with active viral replication. Urine viral load showed a positive correlation with IgM titer (r = 0.22) but a negative correlation with IgG titer (r = -0.28) and IgA titer (r = -0.1). Chronic dialysis patients typically did not have serologic or virologic evidence of active BKV infection. Anti-BKV titers did not rise in patients with JC viruria. In conclusion, measurement of anti-BKV antibody titer and class response can be used to detect the onset of viral replication. ELISAs can be quite specific despite considerable sequence homology between BK virus and JC virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960119      PMCID: PMC1563576          DOI: 10.1128/CVI.00114-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  53 in total

1.  Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients.

Authors:  A S Lok; D Chien; Q L Choo; T M Chan; E K Chiu; I K Cheng; M Houghton; G Kuo
Journal:  Hepatology       Date:  1993-09       Impact factor: 17.425

2.  High incidence of urinary JC virus excretion in nonimmunosuppressed older patients.

Authors:  T Kitamura; Y Aso; N Kuniyoshi; K Hara; Y Yogo
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

3.  Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals.

Authors:  H T Agostini; C F Ryschkewitsch; G L Stoner
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

4.  Enhanced serological and virological findings of Epstein-Barr virus in patients with AIDS and AIDS-related complex.

Authors:  C V Sumaya; R N Boswell; Y Ench; D L Kisner; E M Hersh; J M Reuben; P W Mansell
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

5.  Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains.

Authors:  T Kitamura; C Sugimoto; A Kato; H Ebihara; M Suzuki; F Taguchi; K Kawabe; Y Yogo
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

6.  The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion".

Authors:  M V Ragni; O K Ndimbie; E O Rice; F A Bontempo; S Nedjar
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

7.  Genotypes of human polyomaviruses in urine samples of pregnant women in Taiwan.

Authors:  D Chang; M Wang; W C Ou; M S Lee; H N Ho; R T Tsai
Journal:  J Med Virol       Date:  1996-01       Impact factor: 2.327

8.  Disseminated BK type polyomavirus infection in an AIDS patient associated with central nervous system disease.

Authors:  A Vallbracht; J Löhler; J Gossmann; T Glück; D Petersen; H J Gerth; M Gencic; K Dörries
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

9.  Detection of polyomaviral DNA in clinical samples from immunocompromised patients: correlation with clinical disease.

Authors:  C J Perrons; J D Fox; S B Lucas; N S Brink; R S Tedder; R F Miller
Journal:  J Infect       Date:  1996-05       Impact factor: 6.072

10.  Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients.

Authors:  M W Hornef; G Bein; L Fricke; J Steinhoff; H J Wagner; W Hinderer; H H Sonneborn; H Kirchner
Journal:  Transplantation       Date:  1995-09-15       Impact factor: 4.939

View more
  17 in total

1.  Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation.

Authors:  Thurid Ahlenstiel-Grunow; Lars Pape
Journal:  Pediatr Nephrol       Date:  2018-12-11       Impact factor: 3.714

2.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

Review 3.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

4.  HLA-A01-, -A03-, and -A024-binding nanomeric epitopes in polyomavirus BK large T antigen.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Diana Metes; Marta Bueno; Adriana Zeevi; Ron Shapiro; Raphael Viscidi; Parmjeet S Randhawa
Journal:  Hum Immunol       Date:  2009-05-14       Impact factor: 2.850

5.  BK virus antibody titers and intensity of infections after renal transplantation.

Authors:  Daniel L Bohl; Daniel C Brennan; Caroline Ryschkewitsch; Monique Gaudreault-Keener; Eugene O Major; Gregory A Storch
Journal:  J Clin Virol       Date:  2008-08-03       Impact factor: 3.168

6.  Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.

Authors:  Parmjeet Randhawa; Raphael Viscidi; Joseph J Carter; Denise A Galloway; Tim D Culp; Cathy Huang; Bala Ramaswami; Neil D Christensen
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

7.  Quantitation of human seroresponsiveness to Merkel cell polyomavirus.

Authors:  Diana V Pastrana; Yanis L Tolstov; Jürgen C Becker; Patrick S Moore; Yuan Chang; Christopher B Buck
Journal:  PLoS Pathog       Date:  2009-09-11       Impact factor: 6.823

8.  A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient.

Authors:  Seweryn Bialasiewicz; Gareth Hart; Kimberly Oliver; Shruti P Agnihotri; Igor J Koralnik; Raphael Viscidi; Michael D Nissen; Theo P Sloots; Michael T Burke; Nicole M Isbel; John Burke
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

9.  Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored.

Authors:  David Leuenberger; Per Arne Andresen; Rainer Gosert; Simone Binggeli; Erik H Ström; Sohrab Bodaghi; Christine Hanssen Rinaldo; Hans H Hirsch
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

10.  Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.

Authors:  Carole Fakhry; Jesse R Qualliotine; Zhe Zhang; Nishant Agrawal; Daria A Gaykalova; Justin A Bishop; Rathan M Subramaniam; Wayne M Koch; Christine H Chung; David W Eisele; Joseph Califano; Raphael P Viscidi
Journal:  Cancer Prev Res (Phila)       Date:  2015-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.